With a little help, your immune cells can be potent tumor killers. Steve Gschmeissner/Science Photo Library via Getty Images The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally ...

Cancer patients who received the mRNA-based jab after starting immunotherapy lived significantly longer than those who did not get the vaccine. The mRNA technology from COVID-19 vaccines may help ...

In 1992, the Philippine government created the Bases Conversion and Development Authority (BCDA) with a mission that is as ambitious as it is transformative: turn former military bases into thriving ...

KAISERSLAUTERN, Germany — Germany will front the salaries of nearly 12,000 local national employees at U.S. military bases if the federal government shutdown delays October paychecks, Rheinland-Pfalz ...

The mRNA covid-19 vaccines seem to have an unexpected benefit: extending the lives of people being treated for cancers by boosting the effectiveness of immunotherapy. An analysis of the records of ...

A healthcare worker places vials containing doses of the "Comirnaty" Pfizer BioNTech and Moderna vaccines against the coronavirus disease (COVID-19) on a table at a vaccination centre in Ronda, Spain ...

How forest biodiversity increases productivity via complementary use of canopy space by Zhang Nannan, Chinese Academy of Sciences edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

MAGA and MAHA are happily married in Florida, and nowhere more at home than in Sarasota County, where on a humid October night a crowd of several hundred gathered to honor state Surgeon General Joseph ...

Law enforcement officers shot at a truck outside of a U.S. Coast Guard base in Alameda, Calif., late Thursday night, as protests over the Trump administration’s immigration agenda rage on. The ...

Yosemite National Park has reportedly descended into chaos since the Oct. 1 government shutdown, with increasing reports of illegal BASE jumping from El Capitan, squatters filling up campgrounds and ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.